LEADER 01222nam a2200301 i 4500 001 991000318209707536 008 090702s2002 it 01 0 mul d 020 $a8883340426 035 $ab13840435-39ule_inst 040 $aDip.to SSC$bita 082 04$a348.4965023 110 2 $aScutari$0724113 245 10$aStatuti di Scutari :$bdella prima meta del secolo 14. con le addizioni fino al 1469 /$ca cura di Lucia Nadin ; traduzione in albanese a cura di Pellumb Xhufi con saggi introduttivi di Giovan Battista pellegrini, Oliver Jeans Schmitt e Gherardo Ortalli 260 $aRoma :$bViella,$c2002 300 $a245 p. ;$c24 cm 440 0$aCorpus statutario delle Venezie ;$v15 651 4$aScutari$xStoria$ySec. 14.-15.$vFonti 700 $aPellegrini, Giovanni Battista 700 $aOrtalli, Gherardo 700 $aXhufi, Pellumb 700 $aNadin, Lucia 700 $aSchmitt, Oliver Jens 907 $a.b13840435$b10-12-18$c02-07-09 912 $a991000318209707536 945 $aLE021 SOC24BISA103$g1$i2021000157707$lle021$o-$pE31.00$q-$rl$s- $t0$u0$v0$w0$x0$y.i14989608$z07-07-09 996 $aStatuti di Scutari$91747308 997 $aUNISALENTO 998 $ale021$b02-07-09$cm$da $e-$fmul$git $h0$i0 LEADER 01145oam 2200361 450 001 9910709892103321 005 20180720114118.0 035 $a(CKB)5470000002473331 035 $a(OCoLC)1045069795 035 $a(EXLCZ)995470000002473331 100 $a20180720d2018 ua 0 101 0 $aeng 135 $aurmn||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aInterstate compacts in the United States 210 1$a[Washington, D.C.] :$cThe Law Library of Congress, Global Legal Research Center,$d2018. 215 $a1 online resource (11 pages) 300 $a"June 2018." 320 $aIncludes bibliographical references. 606 $aInterstate agreements$zUnited States 606 $aInterstate relations$zUnited States 615 0$aInterstate agreements 615 0$aInterstate relations 712 02$aLaw Library of Congress (U.S.).$bGlobal Legal Research Directorate, 801 0$bGPO 801 1$bGPO 801 2$bGPO 906 $aBOOK 912 $a9910709892103321 996 $aInterstate compacts in the United States$93305154 997 $aUNINA LEADER 07228nam 2202161z- 450 001 9910557129103321 005 20210501 035 $a(CKB)5400000000040763 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/68429 035 $a(oapen)doab68429 035 $a(EXLCZ)995400000000040763 100 $a20202105d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aAnticancer Agents$eDesign, Synthesis and Evaluation 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 online resource (606 p.) 311 08$a3-0365-0140-1 311 08$a3-0365-0141-X 330 $aThis book is a printed edition of the Special Issue entitled "Anticancer Agents: Design, Synthesis and Evaluation" that was published in Molecules. Two review articles and thirty research papers are included in the Special Issue. Three second-generation androgen receptor antagonists that have been approved by the U.S. FDA for the treatment of prostate cancer have been reviewed. Identification of mimics of protein partners as protein-protein interaction inhibitors via virtual screening has been summarized and discussed. Anticancer agents targeting various protein targets, including IGF-1R, Src, protein kinase, aromatase, HDAC, PARP, Toll-Like receptor, c-Met, PI3Kdelta, topoisomerase II, p53, and indoleamine 2,3-dioxygenase, have been explored. The analogs of three well-known tubulin-interacting natural products, paclitaxel, zampanolide, and colchicine, have been designed, synthesized, and evaluated. Several anticancer agents representing diverse chemical scaffolds were assessed in different kinds of cancer cell models. The capability of some anticancer agents to overcome the resistance to currently available drugs was also studied. In addition to looking into the in vitro ability of the anticancer agents to inhibit cancer cell proliferation, apoptosis, and cell cycle, in vivo antitumor efficacy in animal models and DFT were also investigated in some papers. 517 $aAnticancer Agents 606 $aMedicine and Nursing$2bicssc 610 $a1,2,3-triazole 610 $a2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide 610 $a3,6-dibromocarbazole 610 $a4-(pyridin-4-yloxy)benzamide 610 $a5-bromoindole 610 $a5-fluorouracil 610 $aABCB1 (P-glycoprotein) 610 $aactin 610 $aADME 610 $aallene 610 $aamides/esters 610 $aandrogen receptor 610 $aanti-cancer activity 610 $aanti-neuroinflammation 610 $aanti-ovarian cancer 610 $aanti-tumor 610 $aanticancer 610 $aanticancer activity 610 $aanticancer agent 610 $aanticancer agents 610 $aanticancer compounds 610 $aantimitotic agents 610 $aantioxidant activity 610 $aantiproliferative activity 610 $aantiproliferative agent 610 $aantitumor 610 $aantitumor activity 610 $aapalutamide 610 $aapoptosis 610 $aaromatase 610 $abenzimidazole 610 $abenzofuran-pyrazole 610 $abenzofurans 610 $abeta-lapachone 610 $abivalency 610 $abreast cancer 610 $ac-Met 610 $acarbazole 610 $acell cycle 610 $achemical synthesis 610 $achemoresistance 610 $achrysin analogues 610 $acolchiceine 610 $acolchicine amide 610 $acolchicine analogs 610 $acolchicine sulfonamide 610 $acolon cancer 610 $acomputational docking 610 $acoumarin 610 $acrystal structure 610 $acyanopyridone 610 $acytotoxic activity 610 $acytotoxic properties 610 $acytotoxicity 610 $adarolutamide 610 $aDFT study 610 $adihydroartemisinin 610 $adihydropyranoindole 610 $adocking 610 $adocking studies 610 $adrug discovery 610 $adrug resistance 610 $aE-stereoselective 610 $aenzalutamide 610 $aenzyme inhibition 610 $aestrone derivatives 610 $aflavonoid 610 $aflavonoids 610 $agemcitabine 610 $aHDAC inhibitors 610 $aHeLa 610 $aHepG2 610 $ahydrates 610 $ahydrazine 610 $aIGF-1R 610 $aIL-12 610 $aimmune modulation 610 $aindoleamine 2,3-dioxygenase 610 $ainflammation 610 $ainhibitor 610 $aK562 610 $akinase inhibitor 610 $aMCF-7 610 $aMDM2-p53 interaction 610 $amigration 610 $amimetics 610 $amolecular simulation 610 $aMOLT-4 610 $amultidrug resistance (MDR) reversal 610 $aN-substituted pyrazoline 610 $ananoparticles 610 $anatural product 610 $aneuroblastoma 610 $aNIH3T3 610 $ao-nitro-benzyl 610 $aorganosilicon compounds 610 $aortho-quinones 610 $aovarian cancer 610 $aovercoming drug resistance 610 $aP-glycoprotein 610 $aP-MAPA 610 $aPARP inhibitor 610 $aPARP-1 inhibition 610 $aphenylpyrazolopyrimidine 610 $aphotoactivatable protecting groups 610 $aPI3Ks 610 $aPI3K? inhibitor 610 $aPI3K? inhibitors 610 $apolyvalency 610 $aprodrug 610 $aprostate cancer 610 $aPROTACs 610 $aprotein degradation 610 $aprotein kinase 610 $aprotein-protein interactions 610 $aPyrazole 610 $apyrazolopyridine 610 $apyridotriazine 610 $aquinazolin-4(3H)-one 610 $aquinazolin-4(3H)-thione 610 $aregioselective 610 $asalinomycin 610 $aSchiff base 610 $aSILA-409 (Alis-409) 610 $aSILA-421 (Alis-421) 610 $aSrc 610 $asubstituted pyridine 610 $asynergy 610 $asynthesis 610 $aTalazoparib 610 $atanshione IIA 610 $ataxoids 610 $athiazolidinone 610 $aThienopyrimidine 610 $athienopyrimidinone 610 $athiocolchicine 610 $athiopene 610 $athioxotriazopyridine 610 $aTLR signaling 610 $atopoisomerase II inhibitor 610 $atriazolothiadiazine 610 $atriple-negative breast cancer 610 $atryptophan metabolism 610 $atubulin inhibitors 610 $atumor specificity 610 $aurea 610 $avirtual screening 610 $axanthones 610 $ayeast-based assays 610 $azampanolide 610 $a?III-tubulin 615 7$aMedicine and Nursing 700 $aChen$b Qiao-Hong$4edt$01313308 702 $aChen$b Qiao-Hong$4oth 906 $aBOOK 912 $a9910557129103321 996 $aAnticancer Agents$93031264 997 $aUNINA